Arrakis Therapeutics Competitors, Revenue, Alternatives and Pricing

Claim your profile


Boston, MA USA
Total Funding:$38M
Lead Investor(s):Canaan Partners

City Ranking

State Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Arrakis Therapeutics's estimated annual revenue is currently $14.3M per year.
  • Arrakis Therapeutics received $38.0M in venture funding in February 2017.
  • Arrakis Therapeutics's estimated revenue per employee is $201,000
  • Arrakis Therapeutics's total funding is $38M.

Employee Data

  • Arrakis Therapeutics has 71 Employees.
  • Arrakis Therapeutics grew their employee count by 48% last year.
  • Arrakis Therapeutics currently has 1 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingPricing
Ironwood Pharma...
Infinity Pharma...
Karyopharm Ther...
Carna Bioscienc...
Boston Pharmace...
Vita Data Scien...
Radius Health
Sunovion Pharma...
Ariad Pharmaceu...
Missing a competitor? Contribute!?

Arrakis Therapeutics is a biopharmaceutical company pioneering the discovery of a new class of medicines that directly target RNA. The company's TRYST and PEARL-seq platforms identify new RNA targets and drug candidates to treat diseases unaddressed by today's medicines. Arrakis is developing a proprietary pipeline of RNA-targeted small molecules focused on neurologic diseases, cancer, and rare genetic diseases. Arrakis was founded in 2015 by Russell Petter, Ph.D., Alan Walts, Ph.D., Henri Termeer and Raj Parekh, Ph.D. with a vision to create a proprietary, transformational discovery platform that identifies small-molecule drugs that act directly on disease-causing RNA. The company was established with seed funding provided by Advent Life Sciences and Henri Termeer. The company brings together scientific leaders in RNA structure, chemistry and biology, along with a highly experienced management team and the backing of leading life sciences investors. The company is located in Waltham, Mass.



Number of Employees


Revenue (est)


Current Jobs


Employee Growth %


Total Funding







Executive Contacts

Kristine McKinneyAssociate Director, Target Biology & Translational MedicineEmail Available
Elizabeth HawkinsVice President, Finance & Strategy
Hernan CuervoPrincipal Ivestigator Consultant
Dan KoerwerChief Business OfficerEmail Available
Neil KubicaDirector of RNA Biology
Heather LounsburyVP, Business and Technical OperationsEmail Available
Donovan ChinDirector of Computational Drug DiscoveryEmail Available
Michael SeilerSenior Scientist, Head Of BioinformaticsEmail Available
Meizhong JinSenior DirectorEmail Available
Jim BarsoumSenior Vice President Research

Arrakis Therapeutics News

04/18/2019 - Arrakis Therapeutics Announces $75 Million Series B ...

BUSINESS WIRE)--Arrakis Therapeutics, a biopharmaceutical company pioneering the discovery of a new class of small-molecule medicines ...

04/18/2019 - Arrakis Therapeutics Nabs $75 Million to Create a New Class ...

Arrakis Therapeutics Nabs $75 Million to Create a New Class of rSM ... Massachusetts-based Arrakis Therapeutics will focus its pipeline on ...

04/18/2019 - Gilman buckles in as Arrakis raises $75M, gains momentum

Arrakis is focusing on cancer because it has well-known, well-validated targets that have been considered undruggable. (Arrakis Therapeutics).

Arrakis Therapeutics Funding

DateAmountRoundLead InvestorsReference
2017-02-28$38.0MACanaan PartnersArticle

Arrakis Therapeutics Executive Hires

2017-02-28Michael GilmanChairman/Chief Executive OfficerArticle